Showing results (61-70 of 179) with videos related to

Sort By:
Pageof 18
International Journal of Cardiology. Heart & Vasculature|March 11, 2020
Post-resuscitation myocardial dysfunction in out-of-hospital cardiac arrest patients randomized to immediate coronary angiography versus standard of careLudvig Elfwén, Rickard Lagedal, Sten Rubertsson, et al.
American Heart Journal|April 21, 2009
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatranMichael D Ezekowitz, Stuart Connolly, Amit Parekh, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|September 2, 2015
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillationHein Heidbuchel, Peter Verhamme, Marco Alings, et al.
American Heart Journal|June 15, 2018
Coronary angiography in out-of-hospital cardiac arrest without ST elevation on ECG-Short- and long-term survivalLudvig Elfwén, Rickard Lagedal, Stefan James, et al.
American Heart Journal|December 19, 2015
Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillationJulia Aulin, Agneta Siegbahn, Ziad Hijazi, et al.
Heart (British Cardiac Society)|February 19, 2017
Effects of dabigatran according to age in atrial fibrillationMandy N Lauw, John W Eikelboom, Michiel Coppens, et al.
American Heart Journal|June 25, 2025
Rationale and design of a registry-based randomized controlled study of personalized biomarker-based risk score-guided stroke prevention treatment in atrial fibrillationZiad Hijazi, Lars Wallentin, Håkan Arheden, et al.
Circulation|August 30, 2025
Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation - a Registry-based Multicenter Randomized Controlled StudyJonas Oldgren, Ziad Hijazi, Håkan Arheden, et al.
European Heart Journal|May 10, 2011
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trialJonas Oldgren, Andrzej Budaj, Christopher B Granger, et al.
American Heart Journal|September 7, 2016
Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trialMichael D Ezekowitz, Charles V Pollack, Paul Sanders, et al.
Pageof 18